Liraglutide (Victoza brand only) joins dulaglutide as a funded GLP-1 receptor agonist for treating type 2 diabetes. Prompted by potential supply issues, this listing ensures continued access to a funded GLP-1RA if dulaglutide becomes unavailable.
Special Authority criteria are the same for both subcutaneously administered agents, and actions, efficacy, and adverse event rates are similar. Differences exist in dosing and delivery devices though. Dulaglutide 1.5mg is injected weekly from single-use autoinjector pens with fixed needles, whereas liraglutide is injected daily using a titratable-dose, multi-use, autoinjector pen that requires needles to be prescribed additionally. Liraglutide dose is slowly increased as tolerated, from 0.6mg/day to a maximum of 1.8mg/day.
Read more about initiating treatment with liraglutide or dulaglutide, and print a treatment algorithm here.